Chapter 21 Disease-Modifying Therapies in Motor Neuron Disorders: The Present Position and Potential Future Developments

The management of motor neurone disease

“…[15][16][17] The first placebo controlled trial of riluzole in MND (ALS) included 155 patients who were randomised to take either riluzole (100 mg) or placebo over 21 months. 18 Patients were stratified according to bulbar or limb onset.…”

“…Clinical trials in MND 17 have included many agents that might, on theoretical grounds, modify disease progression: , patient support groups, information (including internet sites), research c Agree on a plan for follow up and support c Send a summary of the interview to the patient and communicate promptly with primary care physician, others involved in care, the patient total lymphoid irradiation, immunoglobulin, electrical stimulation, lamotrigine, topiramate, selegiline, riluzole, acetylcysteine, creatine, vitamin E, verapamil, nimodipine, 3,4diaminopyridine, ciliary neurotrophic factor, insulin-like growth factor I, subcutaneous and intrathecal brain derived neurotrophic factor, gabapentin, superoxide dismutase 1, pimozide, methylcobalamin, procysteine, and xaliproden. Sadly, all have failed to modify disease progression.…”

The management of motor neurone disease

“…[15][16][17] The first placebo controlled trial of riluzole in MND (ALS) included 155 patients who were randomised to take either riluzole (100 mg) or placebo over 21 months. 18 Patients were stratified according to bulbar or limb onset.…”

“…Clinical trials in MND 17 have included many agents that might, on theoretical grounds, modify disease progression: , patient support groups, information (including internet sites), research c Agree on a plan for follow up and support c Send a summary of the interview to the patient and communicate promptly with primary care physician, others involved in care, the patient total lymphoid irradiation, immunoglobulin, electrical stimulation, lamotrigine, topiramate, selegiline, riluzole, acetylcysteine, creatine, vitamin E, verapamil, nimodipine, 3,4diaminopyridine, ciliary neurotrophic factor, insulin-like growth factor I, subcutaneous and intrathecal brain derived neurotrophic factor, gabapentin, superoxide dismutase 1, pimozide, methylcobalamin, procysteine, and xaliproden. Sadly, all have failed to modify disease progression.…”

The management of motor neurone disease

“…[15][16][17] The first placebo controlled trial of riluzole in MND (ALS) included 155 patients who were randomised to take either riluzole (100 mg) or placebo over 21 months. 18 Patients were stratified according to bulbar or limb onset.…”

“…Clinical trials in MND 17 have included many agents that might, on theoretical grounds, modify disease progression: , patient support groups, information (including internet sites), research c Agree on a plan for follow up and support c Send a summary of the interview to the patient and communicate promptly with primary care physician, others involved in care, the patient total lymphoid irradiation, immunoglobulin, electrical stimulation, lamotrigine, topiramate, selegiline, riluzole, acetylcysteine, creatine, vitamin E, verapamil, nimodipine, 3,4diaminopyridine, ciliary neurotrophic factor, insulin-like growth factor I, subcutaneous and intrathecal brain derived neurotrophic factor, gabapentin, superoxide dismutase 1, pimozide, methylcobalamin, procysteine, and xaliproden. Sadly, all have failed to modify disease progression.…”

The management of motor neurone disease

“…[15][16][17] The first placebo controlled trial of riluzole in MND (ALS) included 155 patients who were randomised to take either riluzole (100 mg) or placebo over 21 months. 18 Patients were stratified according to bulbar or limb onset.…”

“…Clinical trials in MND 17 have included many agents that might, on theoretical grounds, modify disease progression: , patient support groups, information (including internet sites), research c Agree on a plan for follow up and support c Send a summary of the interview to the patient and communicate promptly with primary care physician, others involved in care, the patient total lymphoid irradiation, immunoglobulin, electrical stimulation, lamotrigine, topiramate, selegiline, riluzole, acetylcysteine, creatine, vitamin E, verapamil, nimodipine, 3,4diaminopyridine, ciliary neurotrophic factor, insulin-like growth factor I, subcutaneous and intrathecal brain derived neurotrophic factor, gabapentin, superoxide dismutase 1, pimozide, methylcobalamin, procysteine, and xaliproden. Sadly, all have failed to modify disease progression.…”